The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Quinolones in 2005: an update
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA gyrase, topoisomerase IV, and the 4-quinolones.
Drlica, K., & Zhao, X. (1997) · Microbiology and molecular biology reviews : MMBR · doi:10.1128/.61.3.377-392.1997 · Cited by 1,494
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C., & Schentag, J. J. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.5.1073 · Cited by 1,101
Quinolone resistance from a transferable plasmid
Martínez-Martínez, L., Pascual, A., & Jacoby, G. A. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07322-4 · Cited by 1,100
Decreased Susceptibility of Streptococcus pneumoniae to Fluoroquinolones in Canada
Chen, D. K., McGeer, A., de Azavedo, J. C., & Low, D. E. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907223410403 · Cited by 987
Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli
Yoshida, H., Bogaki, M., Nakamura, M., Yamanaka, L. M., & Nakamura, S. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.8.1647 · Cited by 777
1,8-Naphthyridine Derivatives. A New Class of Chemotherapeutic Agents
Lesher, G. Y., Froelich, E. J., Gruett, M. D., Bailey, J. H., & Brundage, R. P. (1962) · Journal of Medicinal and Pharmaceutical Chemistry · doi:10.1021/jm01240a021 · Cited by 766
Variation in antibiotic use in the European Union
Cars, O., Mölstad, S., & Melander, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04972-2 · Cited by 698
Structure-activity and structure-side-effect relationships for the quinolone antibacterials
Domagala, J. M. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/33.4.685 · Cited by 681
Andersson, M. I., & MacGowan, A. P. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg212 · Cited by 627
Pharmacodynamics of Levofloxacin: A New Paradigm for Early Clinical Trials
Preston, S. L. (1998) · JAMA · doi:10.1001/jama.279.2.125 · Cited by 589
Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli
Yoshida, H., Bogaki, M., Nakamura, M., & Nakamura, S. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.6.1271 · Cited by 570
Mechanism of plasmid-mediated quinolone resistance
Tran, J. H., & Jacoby, G. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082092899 · Cited by 564
Resistance to Levofloxacin and Failure of Treatment of Pneumococcal Pneumonia
Davidson, R., Cavalcanti, R., Brunton, J. L., Bast, D. J., de Azavedo, J. C. S., Kibsey, P., Fleming, C., & Low, D. E. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012122 · Cited by 533
Thomas, J. K., Forrest, A., Bhavnani, S. M., Hyatt, J. M., Cheng, A., Ballow, C. H., & Schentag, J. J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.3.521 · Cited by 507
Mechanisms of fluoroquinolone resistance
Hooper, D. C. (1999) · Drug Resistance Updates · doi:10.1054/drup.1998.0068 · Cited by 488
Jacobs, M. R. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg321 · Cited by 467
Plasmid-Mediated Quinolone Resistance in Clinical Isolates of Escherichia coli from Shanghai, China
Wang, M., Tran, J. H., Jacoby, G. A., Zhang, Y., Wang, F., & Hooper, D. C. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2242-2248.2003 · Cited by 467
Outer membrane barrier as a mechanism of antimicrobial resistance
Nikaido, H. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.11.1831 · Cited by 462
Crystal structure of the breakage–reunion domain of DNA gyrase
Cabral, J. H. M., Jackson, A. P., Smith, C. V., Shikotra, N., Maxwell, A., & Liddington, R. C. (1997) · Nature · doi:10.1038/42294 · Cited by 456
Luo, N., Pereira, S., Şahin, O., Lin, J., Huang, S., Michel, L. O., & Zhang, Q. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408966102 · Cited by 451
Persistence of antibiotic resistant bacteria
Andersson, D. I. (2003) · Current Opinion in Microbiology · doi:10.1016/j.mib.2003.09.001 · Cited by 438
Drusano, G. L., Johnson, D. E., Rosen, M., & Standiford, H. C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.3.483 · Cited by 426
Quinolone antimicrobial agents
(1989) · International Journal of Biochemistry · doi:10.1016/0020-711x(89)90066-9 · Cited by 407
Van Bambeke, F., Balzi, E., & Tulkens, P. M. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00291-4 · Cited by 404
Self-citationZhao, X., & Drlica, K. (2001) · Clinical Infectious Diseases · doi:10.1086/321841 · Cited by 397
European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria
Kahlmeter, G. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg312 · Cited by 397
Topoisomerase IV is a target of quinolones in Escherichia coli.
Khodursky, A. B., Zechiedrich, E. L., & Cozzarelli, N. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11801 · Cited by 378
Control of bacterial DNA supercoiling
Drlica, K. (1992) · Molecular Microbiology · doi:10.1111/j.1365-2958.1992.tb01486.x · Cited by 373
Shen, L. L., & Pernet, A. G. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.2.307 · Cited by 369
Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature
Khaliq, Y., & Zhanel, G. G. (2003) · Clinical Infectious Diseases · doi:10.1086/375078 · Cited by 357
Fluoroquinolone resistance among Gram-positive cocci
Hooper, D. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00369-9 · Cited by 320 · cited 1×
“As described previously [28–31], the activity of quinolones stems primarily from the formation of ternary complexes between DNA and type II topoisomerases, namely DNA gyrase and topoisomerase IV, two enzymes that play a critical role in the supercoiling of DNA [32–34].”
BackgroundBlumberg, H. M., Rimland, D., Carroll, D. J., Terry, & Wachsmuth, I. K. (1991) · Journal of Infectious Diseases · doi:10.1093/infdis/163.6.1279 · Cited by 319
Gumbo, T., Louie, A., Deziel, M. R., Parsons, L. M., Salfinger, M., & Drusano, G. L. (2004) · The Journal of Infectious Diseases · doi:10.1086/424849 · Cited by 315
Blondeau, J. M., Zhao, X., Hansen, G., & Drlica, K. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.2.433-438.2001 · Cited by 314
Quinolone generations: natural history or natural selection?
Ball, P. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/oxfordjournals.jac.a020889 · Cited by 302
Obritsch, M. D., Fish, D. N., MacLaren, R., & Jung, R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4606-4610.2004 · Cited by 288
Recanatini, M., Poluzzi, E., Masetti, M., Cavalli, A., & De Ponti, F. (2005) · Medicinal Research Reviews · doi:10.1002/med.20019 · Cited by 285
Interaction of the Plasmid-Encoded Quinolone Resistance Protein Qnr with Escherichia coli DNA Gyrase
Tran, J. H., Jacoby, G. A., & Hooper, D. C. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.1.118-125.2005 · Cited by 283
Ziha-Zarifi, I., Llanes, C., Köhler, T., Pechere, J.-C., & Plesiat, P. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.2.287 · Cited by 276
Expression in Escherichia coli of a New Multidrug Efflux Pump, MexXY, from Pseudomonas aeruginosa
Mine, T., Morita, Y., Kataoka, A., Mizushima, T., & Tsuchiya, T. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.2.415 · Cited by 274
Evolutionary origins of multidrug and drug‐specific efflux pumps in bacteria
Saier, M. H., Paulsen, I. T., Marek, K. S., Pao, S. S., Ronald, A. S., & Nikaido, H. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.03.265 · Cited by 263
Emergence of Plasmid-Mediated Quinolone Resistance in Escherichia coli in Europe
Mammeri, H., Van De Loo, M., Poirel, L., Martinez-Martinez, L., & Nordmann, P. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.1.71-76.2005 · Cited by 261
Gill, M. J., Brenwald, N. P., & Wise, R. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.1.187 · Cited by 259
Willmott, C. J., & Maxwell, A. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.1.126 · Cited by 252
Ho, P.-L., Que, T.-L., Tsang, D. N.-C., Ng, T.-K., Chow, K.-H., & Seto, W.-H. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.5.1310 · Cited by 241
Jumbe, N., Louie, A., Leary, R., Liu, W., Deziel, M. R., Tam, V. H., Bachhawat, R., Freeman, C., Kahn, J. B., Bush, K., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16814 · Cited by 238
Pan, X. S., & Fisher, L. M. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.2.471 · Cited by 237
Jumbe, N., Louie, A., Leary, R., Liu, W., Deziel, M. R., Tam, V. H., Bachhawat, R., Freeman, C., Kahn, J. B., Bush, K., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200316814 · Cited by 236
Comparative Tolerability of the Newer Fluoroquinolone Antibacterials
Ball, P., Mandell, L., Niki, Y., & Tillotson, G. (1999) · Drug Safety · doi:10.2165/00002018-199921050-00005 · Cited by 228
Lomovskaya, O., Lee, A., Hoshino, K., Ishida, H., Mistry, A., Warren, M. S., Boyer, E., Chamberland, S., & Lee, V. J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.6.1340 · Cited by 220
The safety profile of the fluoroquinolones
Bertino, J., & Fish, D. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)80053-3 · Cited by 218
Ho, P. L., Tse, W. S., Tsang, K. W. T., Kwok, T. K., Ng, T. K., Cheng, V. C. C., & Chan, R. M. T. (2001) · Clinical Infectious Diseases · doi:10.1086/319222 · Cited by 216
DNA Gyrase and Topoisomerase IV Are Dual Targets of Clinafloxacin Action in Streptococcus pneumoniae
Pan, X.-S., & Fisher, L. M. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.11.2810 · Cited by 215
Firsov, A. A., Vostrov, S. N., Lubenko, I. Y., Drlica, K., Portnoy, Y. A., & Zinner, S. H. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.5.1604-1613.2003 · Cited by 215
DNA topoisomerase targets of the fluoroquinolones: A strategy for avoiding bacterial resistance
Zhao, X., Xu, C., Domagala, J., & Drlica, K. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.25.13991 · Cited by 213
Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli
Hooper, D. C., Wolfson, J. S., Souza, K. S., Tung, C., McHugh, G. L., & Swartz, M. N. (1986) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.29.4.639 · Cited by 211
Van Bambeke, F. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg224 · Cited by 203
Self-citationBrenwald, N. P., Gill, M. J., & Wise, R. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.8.2032 · Cited by 202
Intracellular pharmacodynamics of antibiotics
Carryn, S., Chanteux, H., Seral, C., Mingeot-Leclercq, M.-P., Van Bambeke, F., & Tulkens, P. M. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00066-7 · Cited by 201
Self-citationPeterson, L. R. (2001) · Clinical Infectious Diseases · doi:10.1086/321846 · Cited by 183
Finch, R., Schürmann, D., Collins, O., Kubin, R., McGivern, J., Bobbaers, H., Izquierdo, J. L., Nikolaides, P., Ogundare, F., Raz, R., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1746-1754.2002 · Cited by 181
Quinolone binding to DNA is mediated by magnesium ions.
Palù, G., Valisena, S., Ciarrocchi, G., Gatto, B., & Palumbo, M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.20.9671 · Cited by 178
Multiple antibiotic resistance in Stenotrophomonas maltophilia
Alonso, A., & Martínez, J. L. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.1140 · Cited by 177
Prevalence of Antibiotic Resistance in Anaerobic Bacteria: Worrisome Developments
Hecht, D. W. (2004) · Clinical Infectious Diseases · doi:10.1086/421558 · Cited by 174
Clinical toxicological aspects of fluoroquinolones
Stahlmann, R. (2002) · Toxicology Letters · doi:10.1016/s0378-4274(01)00509-4 · Cited by 173
Peloquin, C. A. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.1989.00390100083020 · Cited by 167
Bacteria lacking a multidrug pump: A sensitive tool for drug discovery
Hsieh, P.-C., Siegel, S. A., Rogers, B., Davis, D., & Lewis, K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6602 · Cited by 167
Seral, C., Françoise Van Bambeke, A., & Tulkens, P. M. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2283-2292.2003 · Cited by 167
Self-citationKarlowsky, J. A., Thornsberry, C., Jones, M. E., Evangelista, A. T., Critchley, I. A., & Sahm, D. F. (2003) · Clinical Infectious Diseases · doi:10.1086/374052 · Cited by 165
Blondeau, J. M., Hansen, G., Metzler, K., et al. (2004) · Journal of Chemotherapy · doi:10.1080/1120009x.2004.11782371 · Cited by 155
Temafloxacin Syndrome: Review of 95 Cases
Blum, M. D., Graham, D. J., & McCloskey, C. A. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.6.946 · Cited by 154
Pharmacodynamics of the New Fluoroquinolone Gatifloxacin in Murine Thigh and Lung Infection Models
Andes, D. R., & Craig, W. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1665-1670.2002 · Cited by 153
Kahlmeter, G. (2003) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(03)00229-2 · Cited by 152
Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus
Kaatz, G. W., & Seo, S. M. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.12.2733 · Cited by 146
Carryn, S., Françoise Van Bambeke, A., Mingeot‐Leclercq, M., & Tulkens, P. M. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.7.2095-2103.2002 · Cited by 132
Self-citationA large outbreak of multiresistant Pseudomonas aeruginosa strains in north-eastern Germany
Panzig, B., Schröder, G., Pitten, F. A., & Gründling, M. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/43.3.415 · Cited by 131
Takei, M., Fukuda, H., Kishii, R., & Hosaka, M. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3544-3547.2001 · Cited by 123
In vitro and in vivo activity of NY-198, a new difluorinated quinolone
HIROSE, T., Okezaki, E., Kato, H., Ito, Y., Inoue, M., & Mitsuhashi, S. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.6.854 · Cited by 119
Polk, R. E., Johnson, C. K., McClish, D. K., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/422647 · Cited by 117
Alovero, F. L., Pan, X.-S., Morris, J. E., Manzo, R. H., & Fisher, L. M. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.2.320-325.2000 · Cited by 116
Seral, C. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg223 · Cited by 115
Carlier, M.-B., Scorneaux, B., Zenebergh, A., Desnottes, J. F., & Tulkens, P. M. (1990) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/26.suppl_b.27 · Cited by 112
Self-citationPletz, M. W., McGee, L., Jorgensen, J. H., Beall, B., Facklam, R. R., Whitney, C. G., & Klugman, K. P. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.9.3491-3497.2004 · Cited by 112
Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae
Zeller, V., Janoir, C., Kitzis, M.-D., Gutmann, L., & Moreau, N. J. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.9.1973 · Cited by 112
Infectious Complications with Respiratory Pathogens despite Ciprofloxacin Therapy
Lee, B. L., Padula, A. M., Kimbrough, R. C., Jones, S. R., Chaisson, R. E., Mills, J., & Sande, M. A. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108153250719 · Cited by 112
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs
Mouton, J. W., Dudley, M. N., Cars, O., Derendorf, H., & Drusano, G. L. (2002) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(02)00031-6 · Cited by 104
Ball, P. D., Stahlmann, R., Kubin, R., Choudhri, S., & Owens, R. C. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90170-1 · Cited by 102
Dunbar, L. M., Khashab, M. M., Kahn, J. B., et al. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125003304 · Cited by 97
Beyer, R., Pestova, E. V., Millichap, J. G., Stosor, V., Noskin, G. A., & Peterson, L. R. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.798-801.2000 · Cited by 94
Ferrándiz, M.-J., Fenoll, A., Liñares, J., & de la Campa, A. G. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.840-847.2000 · Cited by 91
Kahlmeter, G. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg488 · Cited by 91
Clinical pharmacodynamics of quinolones
Ambrose, P. G., Bhavnani, S. M., & Owens, R. C. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00061-8 · Cited by 90
Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents
Menzies, D. J., Dorsainvil, P. A., Cunha, B. A., & Johnson, D. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01158-0 · Cited by 88
Ciprofloxacin safety in a pediatric population
Jick, S. S. (1997) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199701000-00037 · Cited by 87
Karlowsky, J. A., Thornsberry, C., Jones, M. E., & Sahm, D. F. (2003) · Clinical Infectious Diseases · doi:10.1086/345754 · Cited by 87
Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates Part 2: Human Trials
Schentag, J. J., Meagher, A. K., & Forrest, A. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c419 · Cited by 84
Lau, S.-M., Peng, M.-Y., & Chang, F. (2004) · PubMed · Cited by 83
Croisier, D., Etienne, M., Bergoin, E., Charles, P., Lequeu, C., Piroth, L., Portier, H., & Chavanet, P. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1699-1707.2004 · Cited by 80
Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin
BOWIE, W. R., Willetts, V., & Jewesson, P. J. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.10.1778 · Cited by 79
Fatal Hypoglycemia Associated with Levofloxacin
Friedrich, L. V., & Dougherty, R. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.17.1807.52348 · Cited by 79
Rodríguez-Martínez, J. M. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg388 · Cited by 78
Nickel, J. C. (2005) · The Journal of Urology · doi:10.1097/01.ju.0000141497.46841.7a · Cited by 78
Mechanisms Responsible for Cross-Resistance and Dichotomous Resistance among the Quinolones
Sanders, C. C. (2001) · Clinical Infectious Diseases · doi:10.1086/319369 · Cited by 77
Acute Eosinophilic Hepatitis from Trovafloxacin
Chen, H. J. L., Bloch, K. J., & Maclean, J. A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420517 · Cited by 74
Legakis, N. J., TZOUVELEKIS, L. S., Makris, A. M., & Kotsifaki, H. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.1.124 · Cited by 73
Fischer, M. A., Solomon, D. H., Teich, J. M., & Avorn, J. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.21.2585 · Cited by 72
Janoir, C., Podglajen, I., Kitzis, M.-D., Poyart, C., & Gutmann, L. (1999) · The Journal of Infectious Diseases · doi:10.1086/314888 · Cited by 72
Schentag, J. J., Meagher, A. K., & Forrest, A. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c199 · Cited by 69
Oteo, J., Lázaro, E., de Abajo, F. J., Baquero, F., & Campos, J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.12.5571-5577.2004 · Cited by 67
Pallarés, R., Fenoll, A., & Liñares, J. (2003) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2003.08.004 · Cited by 66
Kern, W. V., Steib–Bauert, M., de With, K., Reuter, S., Bertz, H., Frank, U., & von Baum, H. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh510 · Cited by 66
Kuti, J. L., Le, T. N., Nightingale, C. H., Nicolau, D. P., & Quintiliani, R. (2002) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/59.22.2209 · Cited by 66
Evolutionary Barriers to Quinolone Resistance in Streptococcus pneumoniae
Gillespie, S. H., Voelker, L. L., & Dickens, A. L. (2002) · Microbial Drug Resistance · doi:10.1089/107662902760190617 · Cited by 64
Torsades de pointes associated with fluoroquinolones: Importance of concomitant risk factors
Amankwa, K., Krishnan, S., & Tisdale, J. E. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.11.376 · Cited by 63
Yagüe, G., Morris, J. E., Pan, X.-S., Gould, K. A., & Fisher, L. M. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.2.413-419.2002 · Cited by 62
Pascual, Á., Garcı́a, I., Ballesta, S., & Perea, E. J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.1.12 · Cited by 60
Safety and tolerability of fluoroquinolones
Sprandel, K. A., & Rocivold, K. A. (2003) · Clinical cornerstone · doi:10.1016/s1098-3597(03)90027-5 · Cited by 60
Bellido, J. L. M., Manzanares, M. A. A., Andrés, J., Zufiaurre, M. N. G., Ortiz, G. A., Hernández, M. S., & García-Rodríguez, J. A. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.2.354 · Cited by 57
Allen, G. P., Kaatz, G. W., & Rybak, M. J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2606-2614.2003 · Cited by 54
Long-Term Tolerance and Effectiveness of Moxifloxacin Therapy for Tuberculosis: Preliminary Results
Valerio, G., Bracciale, P., Manisco, V., Quitadamo, M., Legari, G., & BELLANOVA, S. (2003) · Journal of Chemotherapy · doi:10.1179/joc.2003.15.1.66 · Cited by 50
The Changing Face of Antibiotic Prescribing: The Mutant Selection Window
Epstein, B. J., Gums, J. G., & Drlica, K. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1e041 · Cited by 50
Sasabe, H., Kato, Y., SUZUKI, T. A., Itose, M., Miyamoto, G., & Sugiyama, Y. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.065201 · Cited by 50
Jung, R., Fish, D. N., Obritsch, M. D., & MacLaren, R. (2004) · Journal of Hospital Infection · doi:10.1016/j.jhin.2004.03.001 · Cited by 49
Zhao, X., Eisner, W., Perl-Rosenthal, N., Kreiswirth, B. N., & Drlica, K. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.1023-1027.2003 · Cited by 49
Mechanisms of Fluoroquinolone Transport by Human Neutrophils
Walters, J. D., Zhang, F., & Nakkula, R. J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2710 · Cited by 48
Klepser, M. E., Ernst, E. J., Petzold, C., Rhomberg, P. R., & Doern, G. V. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.3.673-678.2001 · Cited by 48
Role of newer fluoroquinolones in lower respiratory tract infections
Lode, H. M. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf024 · Cited by 45
Carrier-Mediated Hepatic Uptake of Quinolone Antibiotics in the Rat
Sasabe, H., Terasaki, T., Tsuji, A., & Sugiyama, Y. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36787-4 · Cited by 42
Li, X., Mariano, N., Rahal, J. J., Urban, C. M., & Drlica, K. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.11.4460-4462.2004 · Cited by 41
Corrao, G., Botteri, E., Bagnardi, V., Zambon, A., Carobbio, A., Falcone, C., & Leoni, O. (2004) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1019 · Cited by 40
Linde, H. ‐. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh036 · Cited by 40
Ricci, V., Peterson, M. L., Rotschafer, J. C., Wexler, H. M., & Piddock, L. J. V. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.4.1344-1346.2004 · Cited by 39
The Role of Clonality in the Global Spread of Fluoroquinolone‐Resistant Bacteria
Klugman, K. P. (2003) · Clinical Infectious Diseases · doi:10.1086/367935 · Cited by 37
Nix, D. E., Sands, M. F., Peloquin, C. A., et al. (1987) · PubMed · Cited by 37
Fluoroquinolones in the treatment of meningitis
Cottagnoud, P., & Täuber, M. G. (2003) · Current Infectious Disease Reports · doi:10.1007/s11908-003-0011-0 · Cited by 36
Chaniotaki, S., Giakouppi, P., TZOUVELEKIS, L. S., Panagiotakos, D. B., Kozanitou, M., Petrikkos, G. L., Avlami, A., & Vatopoulos, A. C. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.00807.x · Cited by 36
O’Donnell, J. A., & Gelone, S. P. (2004) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2004.04.011 · Cited by 35
Streptococcus pneumoniae,Brooklyn, New York: Fluoroquinolone Resistance at our Doorstep
Quale, J. M., Landman, D., Ravishankar, J., Flores, C., & Bratu, S. (2002) · Emerging infectious diseases · doi:10.3201/eid0806.010275 · Cited by 33
Nakata, K., Maeda, H., Fujii, A., et al. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.1.188 · Cited by 32
Fluoroquinolones as Chemotherapeutics Against Mycobacterial Infections
Jacobs, M. R. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043383296 · Cited by 31
Empiric Therapy of Community-Acquired Pneumonia
Cunha, B. A. (2004) · CHEST Journal · doi:10.1378/chest.125.5.1913 · Cited by 31
Mutant prevention concentrations of ciprofloxacin and enrofloxacin for Salmonella enterica
Randall, L. P., Cooles, S. W., Piddock, L. J. V., & Woodward, M. J. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh360 · Cited by 31
Oizumi, N., Kawabata, S., Hirao, M., Watanabe, K., Okuno, S., Fujiwara, T., & Kikuchi, M. (2001) · Journal of Infection and Chemotherapy · doi:10.1007/s101560100034 · Cited by 28
Appelbaum, P. C., Gillespie, S. H., Burley, C. J., & Tillotson, G. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.02.017 · Cited by 28
Grohs, P., Houssaye, S., Aubert, A., Gutmann, L., & Varon, E. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.11.3542-3547.2003 · Cited by 25
Carbon, C., Cars, O., & Christiansen, K. (2002) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.8.s.2.8.x · Cited by 24
Sato, K. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg343 · Cited by 24
Minimizing Potential Resistance: The Molecular View—A Comment on Courvalin and Trieu‐Cuot
Hooper, D. C. (2001) · Clinical Infectious Diseases · doi:10.1086/321842 · Cited by 21
Role of newer fluoroquinolones in lower respiratory tract infections
Lode, H. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf133 · Cited by 20
Moving from recommendation to implementation and audit: Part 2. Review of interventions and audit
Christiansen, K., Carbon, C., & Cars, O. (2002) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.8.s.2.9.x · Cited by 19
Ben-David, D., & Rubinstein, E. (2002) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200204000-00009 · Cited by 19
Levofloxacin: update and perspectives on one of the original ‘respiratory quinolones’
Fish, D. N. (2003) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.1.3.371 · Cited by 19
Treatment of Skin and Soft Tissue Infections
Karchmer, A. W. (2014) · ASM Press eBooks · doi:10.1128/9781555817817.ch19 · Cited by 18
Bounds, S. J., Nakkula, R. J., & Walters, J. D. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.10.2609-2614.2000 · Cited by 17
Jonas, D., Schwab, F., Gastmeier, P., R�den, H., Daschner, F. D., & Meyer, E. (2004) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-004-0804-9 · Cited by 13
Treatment of Osteomyelitis and Septic Arthritis
Bernard, L., Waldvogel, F. A., & Lew, D. (2014) · ASM Press eBooks · doi:10.1128/9781555817817.ch15 · Cited by 8
Treatment of Bacterial Meningitis and Other Central Nervous System Infections
Tunkel, A. R., & Scheld, W. M. (2014) · ASM Press eBooks · doi:10.1128/9781555817817.ch17 · Cited by 3
Cited by
Pham, T. D. M., Ziora, Z. M., & Blaskovich, M. A. T. (2019) · MedChemComm · doi:10.1039/c9md00120d · Cited by 785
Quinolones: from antibiotics to autoinducers
Heeb, S., Fletcher, M. P., Chhabra, S. R., Diggle, S. P., Williams, P., & Cámara, M. (2011) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2010.00247.x · Cited by 595
Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium
Mesaros, N., Nordmann, P., Plésiat, P., Roussel-Delvallez, M., Van Eldere, J., Glupczynski, Y., Van Laethem, Y., Jacobs, F., Lebecque, P., Malfroot, A., et al. (2007) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01681.x · Cited by 585
Self-citationQuinolones: Mechanism, Lethality and Their Contributions to Antibiotic Resistance
Bush, N. G., Diez-Santos, I., Abbott, L. R., & Maxwell, A. (2020) · Molecules · doi:10.3390/molecules25235662 · Cited by 413
Plasmid-mediated quinolone resistance: an update
Rodríguez-Martínez, J. M., Velasco, C., Pascual, Á., Cano, M. E., Martínez-Martínez, L., Martínez-Martínez, L., & Pascual, Á. (2011) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-010-0120-2 · Cited by 306
Metadata
- Authors
- Van Bambeke, F., Michot, J.-M., Van Eldere, J., & Tulkens, P. M.
- Venue
- Clinical Microbiology and Infection
- Publisher
- Elsevier BV
- Published
- 2005-04
- Volume
- 11
- Issue
- 4
- Pages
- 256-280
- ISSN
- 1198-743X (ISSN-L)
- OpenAlex
- W2148620725
- Cited by
- 342
- References
- 157
- FWCI
- 12.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.